Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PM-012
- Development stage
- Unknown
- Lead developer
- Mediforum
- Modality
- Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
PM-012 is a botanical drug candidate developed by the South Korean company Mediforum for the treatment of dementia and Alzheimer's disease. It is a standardized multi-component extract based on the traditional Korean herbal formula Yukmi-jihwang-tang, which comprises six medicinal herbs: *Rehmannia glutinosa*, *Cornus officinalis*, *Dioscorea batatas*, *Alisma orientale*, *Poria cocos*, and *Paeonia suffruticosa*. The therapeutic mechanism of PM-012 involves neuroprotection, inhibition of amyloid-beta aggregation, and enhancement of cognitive function. Mediforum initiated Phase 3 clinical trials in South Korea in 2019, positioning the drug as a potential alternative or adjunct to existing synthetic acetylcholinesterase inhibitors with a focus on a lower side-effect profile.
- Other names
- PM012PM-012PM 012
02
Targets
Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on PM-012.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PM-012.